34 matches for your search in the start-up spotlight
rss
Neogap Therapeutics' PIOR technology identifies targets for personalised liver cancer immunotherapies
17-Feb-2025
A new study published in the scientific journal Gut examines how immune system T cells respond to tumours in patients with advanced liver cancer (HCC). Using Neogap Therapeutics' PIOR® software platform, the researchers have identified tumour-specific mutations, which may contribute to the ...
Including cell therapy candidates and related platform technologies
03-Dec-2024
Roche announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc., a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies. Based in San Diego, California, Poseida’s R&D portfolio includes pre-clinical and ...
16-Oct-2024
invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, announced that the company has raised €8.2 million in a Series A fundraising that includes strong participation from existing shareholders and Ligand Pharmaceuticals. Ligand recently acquired APEIRON, the ...
PL BioScience closes Series A financing in the amount of 7.8 million euros
09-Aug-2024
PL BioScience GmbH has successfully completed a Series A financing round. The growth financing round attracted significant investments from AVANT BIO (New York), LePure Biotech (Shanghai), b.value AG (Dortmund) and better ventures (Munich). The four partners contribute their experience in deep ...
Max Delbrück Centre and biotech start-up AlgenScribe cooperate
29-Jul-2024
The Max Delbrück Center, Berlin, and the biotech company AlgenScribe from Nice have agreed to cooperate to further develop their gene-editing tools. The aim is to utilize synergies, accelerate research, and ultimately develop cell therapies for genetically determined diseases. A special kind of ...
Start-up develops first-in-class efficacy-enhanced TCR-T cells for solid tumors that are not addressed by existing therapies
28-May-2024
Captain T Cell, a spin-off from the Max Delbrück Center, raised €8.5 million in startup funding. The startup focuses on developing T cells to target solid tumors. The funds are intended to move a new generation of T cell therapies towards the clinic. Captain T Cell GmbH announced the successful ...
Award-winning technology combines a bioreactor and a centrifuge into one single vessel for the first time
23-May-2024
Over the last decade, several breakthrough Cell and Gene Therapy products have been approved in the USA and Europe to turn stem cells and immune cells into ‘living cures’, bringing hope to millions living with life-threatening conditions. However, these treatments remain out of reach for 98% of ...
First regulatory T cell therapy from an unmatched third-party donor
26-Mar-2024
ActiTrexx GmbH, a clinical-stage company focusing on the activation of regulatory T cells, has treated the first patient with Actileucel, its novel cell therapy for the prevention and treatment of Graft-versus-Host Disease (GvHD) in patients receiving an allogeneic haematopoietic stem cell ...
“MIP Discovery’s synthetic affinity reagents hold huge potential to overcome bottlenecks in cell and gene therapy development and production”
28-Feb-2024
MIP Discovery, an innovative developer of non-biological affinity reagents designed to accelerate the development and production of cell and gene therapies, announced it has closed a £7 million GBP (~$9 million USD) Series A financing round, led by Mercia Ventures. Existing investor Calculus ...
Start-ups presented their ideas at the “Munich Demo Day” of the BioTech Bootcamp of BioM and SmiLe
12-Dec-2023
As part of this year's BioTech Bootcamp ofBioM Biotech Cluster Development GmbH and the life science business incubator„SmiLe Incubator“ from Lund, Sweden, the international, eight-week training program for prospective founders and young companies climaxed in the Munich “Demo Week”. Nine teams, ...
